Akebia Therapeutics (AKBA) Q3 2024 Earnings
AKBA·Reported November 7, 2024·Before market open
Akebia Therapeutics reported Q3 2024 revenue of $37.4M, missed analyst consensus of $40.9M by $3.5M. Diluted EPS came in at $-0.10, missed the $-0.05 consensus by $0.05.
Revenue
$37.4Mmissed by $3.5M
Consensus: $40.9MDiluted EPS
$-0.10missed by $0.05
Consensus: $-0.05
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Akebia Therapeutics's Q3 2024 earnings report.
Akebia Therapeutics (AKBA) reported Q3 2024 earnings on November 7, 2024 before market open.
Akebia Therapeutics reported revenue of $37.4M and diluted EPS of $-0.10 for Q3 2024.
Revenue missed the consensus estimate of $40.9M by $3.5M. EPS missed the consensus estimate of $-0.05 by $0.05.
You can read the 10-Q periodic report (0001628280-24-045979) directly on SEC EDGAR. The filing index links above go to sec.gov.